Britain's Oxford University said today it would study whether the world's best-selling prescription medicine, adalimumab, was an effective treatment for Covid-19 patients, the latest effort to repurpose existing drugs as potential coronavirus therapies.
The AVID-CC trial will test the anti-tumour necrosis factor (anti-TNF) drug and will be aimed at treating people in the community, especially in care homes. It will enrol up to 750 patients from community care settings throughout the UK.
LEAVE A COMMENT Your email address will not be published. Required fields are marked*
Rare pink diamond to go under hammer in Geneva
Italy votes as far-right eyes historic victory
Russia stiffens penalty for refusal to fight, replaces top general
On poll eve, Italy braces for potential far-right win
Lavrov slams the West for ‘grotesque’ Russophobia
UK government unveils historic tax cuts as recession looms
NGO: Over 1,000 arrested in anti-mobilisation protests
Putin orders the first Russian mobilisation since World War II
Britain cleans up, looks to future after queen’s funeral